Other amylin-based molecules which are in early stage clinical trials include long-acting amylin agonists and a dual amylin and calcitonin RA (Table 1)
We believe that sustainable weight loss should be achieved through science, empathy, and a transparent approach
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al
One of the most promising drug classes in recent years is GLP-1 receptor agonists, including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro).These medications have revolutionized weight loss and diabetes management, with additional potential benefits in reducing risks for conditions like sleep apnea, cardiovascular disease, and even alcohol dependence
Let our medical team know youre interested in medical weight loss treatment
doi: 10.1038/s41574-024-01047-y, 43